Topical Collection

Acute Myeloid Leukemia (AML)

Message from the Collection Editor

Precision medicine has opened the door to personalized therapy for specific Acute Myeloid Leukemia (AML) patient populations with promising results. Several targeted therapies have been approved or are being tested for specific mutations (i.e., FLT3, IDH, BCL-2, and TP53), obtaining improvements in clinical outcomes and less toxicity as compared with some intensive or non-intensive regimens, potentially allowing for combination therapy. Appropriate clinical development and use of non-approved combinations in the context of clinical trials should be recommended in order to avoid unexpected adverse events in AML patients.

This Special Issue will highlight the critical role of supportive care and appropriate management of new drugs and combinations to ensure therapeutic success in AML cases. In addition, we will critically assess epidemiological and real-life evidence of AML outcomes beyond the clinical trial setting.

Collection Editor

Dr. Pau Montesinos

Hematology Department, La Fe University and Polytechnic Hospital, 46026 Valencia, Spain



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/64515

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

